Regenxbio Inc
RGNX9.190USD
-0.170-1.82%
Market hours （ET）Quotes delayed by 15 min
463.07MMarket Cap
LossP/E TTM
More Details of Regenxbio Inc Company
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Company Info
Ticker SymbolRGNX
Company nameRegenxbio Inc
IPO dateSep 17, 2015
CEOMr. Curran M. Simpson
Number of employees353
Security typeOrdinary Share
Fiscal year-endSep 17
Address9804 Medical Center Drive
CityROCKVILLE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code20850
Phone12405528181
Websitehttps://regenxbio.com/
Ticker SymbolRGNX
IPO dateSep 17, 2015
CEOMr. Curran M. Simpson
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-55.17%
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
53.97K
-8.33%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
23.73K
-24.58%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+63.21%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+68.83%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+68.83%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
17.59K
-1.31%
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
Dr. David C. (Dave) Stump, M.D.
Dr. David C. (Dave) Stump, M.D.
Independent Director
Independent Director
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-55.17%
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
53.97K
-8.33%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
23.73K
-24.58%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+63.21%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+68.83%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+68.83%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Redmile Group, LLC
9.45%
BlackRock Institutional Trust Company, N.A.
8.45%
The Vanguard Group, Inc.
6.77%
JP Morgan Asset Management
5.91%
Fox (Allan Mark)
5.74%
Other
63.67%
Shareholders
Shareholders
Proportion
Redmile Group, LLC
9.45%
BlackRock Institutional Trust Company, N.A.
8.45%
The Vanguard Group, Inc.
6.77%
JP Morgan Asset Management
5.91%
Fox (Allan Mark)
5.74%
Other
63.67%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
33.86%
Investment Advisor
31.15%
Hedge Fund
12.71%
Individual Investor
7.63%
Research Firm
6.86%
Sovereign Wealth Fund
2.06%
Pension Fund
0.28%
Bank and Trust
0.26%
Family Office
0.26%
Other
4.93%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
421
48.19M
95.62%
-3.63M
2025Q1
446
48.46M
96.35%
-3.90M
2024Q4
444
48.16M
97.22%
-4.82M
2024Q3
444
49.64M
100.43%
-4.45M
2024Q2
437
49.30M
99.98%
-3.20M
2024Q1
451
48.23M
99.21%
+414.63K
2023Q4
436
43.62M
98.84%
-7.14M
2023Q3
439
43.73M
99.56%
-6.26M
2023Q2
439
43.86M
100.57%
-5.31M
2023Q1
456
44.07M
101.46%
-1.49M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Redmile Group, LLC
4.79M
9.52%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.92M
7.77%
+48.66K
+1.26%
Mar 31, 2025
The Vanguard Group, Inc.
3.47M
6.89%
+495.83K
+16.65%
Mar 31, 2025
JP Morgan Asset Management
2.95M
5.85%
+36.88K
+1.27%
Mar 31, 2025
Fox (Allan Mark)
2.90M
5.76%
+7.77K
+0.27%
May 30, 2025
State Street Global Advisors (US)
1.07M
2.12%
-1.12M
-51.23%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.09M
2.17%
-19.59K
-1.76%
Mar 31, 2025
Goldman Sachs & Company, Inc.
643.28K
1.28%
-77.14K
-10.71%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.11M
2.2%
+12.72K
+1.16%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.15M
2.28%
-23.70K
-2.02%
Mar 31, 2025
View more
Related ETFs
Updated: Tue, Sep 2
Updated: Tue, Sep 2
Name
Proportion
WisdomTree BioRevolution Fund
2.01%
Virtus LifeSci Biotech Clinical Trials ETF
0.99%
iShares Neuroscience and Healthcare ETF
0.95%
Global X Genomics & Biotechnology ETF
0.47%
JPMorgan Fundamental Data Science Small Core ETF
0.33%
ALPS Medical Breakthroughs ETF
0.26%
SPDR S&P Biotech ETF
0.13%
iShares Health Innovation Active ETF
0.09%
Direxion Daily S&P Biotech Bull 3X Shares
0.08%
Fidelity Enhanced Small Cap ETF
0.08%
View more
WisdomTree BioRevolution Fund
Proportion2.01%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.99%
iShares Neuroscience and Healthcare ETF
Proportion0.95%
Global X Genomics & Biotechnology ETF
Proportion0.47%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.33%
ALPS Medical Breakthroughs ETF
Proportion0.26%
SPDR S&P Biotech ETF
Proportion0.13%
iShares Health Innovation Active ETF
Proportion0.09%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.08%
Fidelity Enhanced Small Cap ETF
Proportion0.08%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
